Authors:

Saeed Karimi[email protected]Department of Ophthalmology, Torfeh Medical Center, Shahid Beheshti University of Medical Sciences, Tehran

Mohsen Zare[email protected]Department of Ophthalmology, Torfeh Medical Center, Shahid Beheshti University of Medical Sciences, Tehran

Pantea Karbasi[email protected]Department of Ophthalmology, Torfeh Medical Center, Shahid Beheshti University of Medical Sciences, Tehran

Morteza Hosseini[email protected]Department of Ophthalmology, Torfeh Medical Center, Shahid Beheshti University of Medical Sciences, Tehran

Abstract:

Purpose: To report a case of unexplained perivascular chorioretinal atrophy temporally associated with ranolazine use.
Case Report: A 64-year-old man with chronic stable angina pectoris was referred to our retina clinic with a complaint of an inferior visual field defect in the right eye over the last 1 month. The symptom onset coincided with the prescription of ranolazine extended-release 500 mg daily and slowly progressed over this period. Central and color vision were normal, and relative afferent pupillary defect was negative. Fundus exam showed chorioretinal atrophy in both eyes along the main vascular arcades, which was more prominent in the right eye and along the superior temporal arcade. Visual field assessment disclosed a double arcuate scotoma in both eyes. Swept-source optical coherence tomography showed outer retina, retinal pigment epithelium, and choriocapillaris atrophy in the extrafoveal area. Fundus autofluorescence showed hypo-autofluorescence, and fluorescein angiography revealed staining along the vascular arcades. Electroretinogram disclosed abnormal photopic and scotopic responses. All findings were more prominent in the right eye and along the superior temporal arcade. Ranolazine intake was stopped. Three months after drug cessation, the patient’s visual field and electroretinogram improved.
Conclusion: This is the first case report on ranolazine-associated chorioretinal toxicity, highlighting the necessity of further studies on potential side effects of even short-term exposure to this drug.

Keywords: Drug-related Side Effects, Ranolazine, Retinal Toxicity

References:

1. Scirica BM, Morrow DA, Hod H, Murphy SA, Belardinelli L, Hedgepeth CM, et al. Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: Results from the Metabolic Efficiency With Ranolazine for Less Ischemia in Non ST-Elevation Acute Coronary Syndrome Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) randomized controlled trial. Circulation 2007;116:1647-1652.

2. Reed M, Kerndt CC, Gopal S, Pellegrini MV, Nicolas D. Ranolazine. StatPearls Publishing; 2025.

3. Jerling M. Clinical pharmacokinetics of ranolazine. Clin Pharmacokinet 2006;45:469-491.

4. Koren MJ, Crager MR, Sweeney M. Long-term safety of a novel antianginal agent in patients with severe chronic stable angina: The Ranolazine Open Label Experience (ROLE). J Am Coll Cardiol 2007;49:1027-1034.

5. Nichols CJ, Mieler WF. Severe retinal vaso-occlusive disease secondary to procainamide-induced lupus. Ophthalmology 1989;96:1535-1540.

6. Wang AG, Cheng HC. Amiodarone-associated optic neuropathy: Clinical review. Neuroophthalmology 2016;41:55-58.

7. Lawrenson JG, Kelly C, Lawrenson AL, Birch J. Acquired colour vision deficiency in patients receiving digoxin maintenance therapy. Br J Ophthalmol 2002;86:1259-1261.

8. Wulff H, Castle NA, Pardo LA. Voltage-gated potassium channels as therapeutic targets. Nat Rev Drug Discov 2009;8:982-1001.

9. Mamaeva D, Jazouli Z, DiFrancesco ML, Erkilic N, Dubois G, Hilaire C, et al. Novel roles for voltage-gated T-type Ca2+ and ClC-2 channels in phagocytosis and angiogenic factor balance identified in human iPSC-derived RPE. FASEB J 2021;35:e21406.

10. Xu P, Zou W, Yin W, Chen G, Gao G, Zhong X. Ion channels research in hPSC-RPE cells: Bridging benchwork to clinical applications. J Transl Med 2024;22:1073.